Onglyza
AZ and Takeda diabetes drugs get FDA safety update
April 15, 2015Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, diabetes, saxagliptin
An FDA advisory committee has said that the labels of two type 2 diabetes drugs should be changed to warn …
AstraZeneca diabetes drug could ‘significantly’ increase mortality
April 13, 2015Research and Development, Sales and Marketing AstraZeneca, FDA, Nesina, Onglyza, Takeda, alogliptin, cardiovascular, saxagliptin
AstraZeneca’s diabetes drug Onglyza may lead to a ‘significant increase’ in risk of death according to a new analysis from …
Scottish reforms proven to work says SMC
March 4, 2015Sales and Marketing NHS, NICE, Onglyza, PACE, SMC, Scotland, anne lee, scottish
The chief pharma advisor for the Scottish Medicines Consortium Anne Lee says changes to its processes have contributed to improved …
AstraZeneca diabetes drug approved for use in Scotland
November 11, 2014Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2
The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …
AstraZeneca ‘rejects Pfizer bid’
April 22, 2014Research and Development, Sales and Marketing AstraZeneca, Byetta, Onglyza, Pfizer, Soriot, merger
AstraZeneca has rebuffed a £60 billion bid from Pfizer, according to media reports. Both companies have declined to comment on …
AstraZeneca ‘simplifies decision-making’
February 4, 2014Sales and Marketing AstraZeneca, BMS, Byetta, Forxiga, Onglyza, diabetes
AstraZeneca has completed its $4.3 billion acquisition of Bristol-Myers Squibb’s diabetes business, giving the company control over several big-name brands …
BMS sells diabetes stake to partner AstraZeneca
December 19, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, Onglyza, diabetes, komboglyze
AstraZeneca will buy out Bristol-Myers Squibb’s stake in its diabetes alliance in a potential $4.3 billion deal. AZ will pay …
BMS invests $15 million in Asian diabetes programme
June 11, 2012Sales and Marketing Asia, BMS, China, India, Onglyza, diabetes
Bristol-Myers Squibb has invested $15 million into its ‘Together on Diabetes’ campaign in India and China. Together on Diabetes is …
Onglyza cleared for use with insulin
November 29, 2011Sales and Marketing AstraZeneca, Merck, Onglyza, diabetes, insulin
European regulators have approved a licence extension for Bristol-Myers Squibb and AstraZeneca’s type II diabetes treatment Onglyza. The oral DPP-4 …
Onglyza expands European licence
March 4, 2011Sales and Marketing AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes
European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that …
Five-year cardiovascular study planned for Onglyza
March 10, 2010Research and Development, Sales and Marketing DPP-4, Onglyza, diabetes
Bristol-Myers Squibb and AstraZeneca are to embark on a five-year study of Onglyza in type II diabetes patients who may …
AZ-BMS launch Onglyza in Europe
October 19, 2009Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes
Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …
